Home Page - ChinaBio® Today

Up to fifteen semi-finalists will be selected from previously submitted business plans. These finalists will be invited to attend the SEED Finalists Coaching Day to be held on March 2, 2010 in Shanghai where they will receive hands-on coaching. Presentations and additional coaching will be provided by the organizers and others during this one-day event. Attendees will include semi-finalists and other entrants, judges/coaches, and anyone interested in entrepreneurship and China’s life science industry.

>> See www.SEED2010.com for more information on the SEED events Register Now for Free!

ChinaBio® Today - Focused solely on China biotech...

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotechnology companies and industry events, as well as global issues affecting the China life science market.

Email subscriptions are free. Just click here to register for free daily summaries of key events in China biotech. Paid subscriptions provide full access to all articles and analysis, including the over 2000 articles we've published on the biotech industry over the last four years. There is also an option to contact our analysts to answer your questions. Click here to learn more about our subscription plans.

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

Gorbec to Open GMP Analytical Lab in China (in: News & Analysis) Feb 8, 2010: Gorbec Pharmaceutical Services, a North Carolina company that offers CRO and CMO services, will open a GMP-compliant analytical laboratory in Yantai, China, which is located in the northeast province of Shandong. The company said the new facility will expand its ability to provide analytical services in support of NDAs. Gorbec expects that clients from its US customer base as well as Asian biopharmas will take advantage of the lab’s offerings. More details...

3SBio Gains China Rights to Another Drug for Dialysis Patients (in: Deals & Financings) Feb 8, 2010: 3SBio Inc. (沈阳三生制药) in-licensed the China rights to a phosphate binder, Nephoxil®, from Panacor Bioscience Ltd. of Taiwan. Phosphate binders are routinely prescribed for end stage renal disease, the same population served by 3SBio’s major products, the recombinant anemia drugs EPIAO and TPIAO. More details...

Stock Symbol: (NSDQ: SSRX)

The Week in Review: New Investments in China Life Science (in: Week in Review) Feb 6, 2010: BioMarin Pharma will pay up to $96 million to acquire LEAD Therapeutics, which is connected to ShangPharma; Tongjitang Chinese Medicines will acquire Guiyang Liquor Factory for $17.7 million; Zhejiang Hisun Pharma will make a $10 million investment in Sagent Pharma of the US; Sanofi-Aventis formed a consumer healthcare joint venture with Minsheng Pharma; China Medicine Corp. closed a previously announced $70 million private placement; Huifeng Bio-Pharma predicts 2010’s revenues will jump 50% or more; Achillion Pharma out-licensed the China rights for a hepatitis B treatment to GCA Therapeutics; Response Biomedical signed up a second partner to market its diagnostic products in China; Sinobiopharma’s most important product is now covered by China’s basic health insurance plan; NeoStem’s China subsidiary received manufacturing approval for its new facility; and finally, China will establish pilot programs to get hospital reform underway. More details...

Stock Symbol: (NSDQ: BMRN) (NYSE: TCM) (SHA: 600267) (NYSE: SNY) (OCTBB: CHME) (OTCBB: HFGB) (NSDQ: ACHN) (TSX: RBM, OTCBB: RPBIF) (OTCBB: SNBP) (NYSE Amex: NBS)

Huifeng Bio-Pharma Expects 50% Revenue Increase in 2010 (in: News & Analysis) Feb 5, 2010: Huifeng Bio-Pharmaceutical Technology reported it expects 2009 revenues to be between $13 million and $14 million, about 30% better than last year. Net income is forecast to be as much as $3 million. The big news is that Huifeng predicts 2010’s revenues will be in a range between $20 million and $25 million, an increase of 50% or more. More details...

Stock Symbol: (OTCBB: HFGB)

BioMarin Buys LEAD Therapeutics of California and Shanghai (in: Deals & Financings) Feb 5, 2010: BioMarin Pharmaceutical of Novato, California, will acquire LEAD Therapeutics of San Bruno, California and Shanghai, a drug discovery company that has a strategic relationship with ShangPharma, a CRO. ShangPharma has a scientific staff dedicated to doing LEAD’s chemistry work, and it has made an investment in ShangPharma. BioMarin will pay $18 million upfront and an additional $11 million when LEAD’s key compound files for IND. The deal could ultimately be worth $96 million with milestones. More details...

Stock Symbol: (NSDQ: BMRN)

China’s State Council Reveals Hospital Reform Plan (in: Gov't & Regulatory) Feb 4, 2010: China will implement its nationwide public hospital reform by establishing pilot programs that move away from the profit motive, which has been in effect for the past years. The programs will be spread across the country, with at least one located in each province, autonomous region and municipality. Unfortunately, details of the reform plan are sketchy. More details...

Tongjitang Pays $18 Million to Acquire Guiyang Liquor (in: Deals & Financings) Feb 3, 2010: Tongjitang Chinese Medicines Company, a company focused on modernized TCM products, has set up a joint venture to acquire Guiyang Liquor Factory, a state-owned company, for 120.6 million RMB ($17.7 million) in cash. Tongjitang, which owns 95% of the joint venture, will pay its share of the consideration in full by February 2010. Though the company is said to be profitable, its revenues in 2008 were only 19 million RMB ($2.8 million). More details...

Stock Symbol: (NYSE: TCM)

Zhejiang Hisun Pharma Invests in US-based Sagent Pharma (in: Deals & Financings) Feb 3, 2010: Zhejiang Hisun Pharmaceutical Co. Ltd. revealed that it will make a $10 million investment in Sagent Pharma, a relatively new company headquartered near Chicago, Illinois. The company will purchase 7 million shares at $1.40 each in privately held Sagent, equivalent to a 4.5% stake. More details...

Stock Symbol: (SHA: 600267)

Response Biomedical Signs Second China Partner (in: News & Analysis) Feb 2, 2010: Response Biomedical Corporation signed up a second partner to market its diagnostic products in China. Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China will sell Response Biomedical’s cardiac offerings as private label products. O&D Biotech Co. will continue to market the same diagnostic tests as co-branded RAMP® products on both the RAMP® and RAMP® 200 Readers. More details...

Stock Symbol: (TSX: RBM, OTCBB: RPBIF)

GCA Therapeutics to Commercialize Achillion’s HBV Treatment in China (in: Deals & Financings) Feb 2, 2010: Achillion Pharmaceuticals out-licensed the China rights for elvucitabine, to GCA Therapeutics, Ltd. (GCAT) of Jersey City, New Jersey. Elvucitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). GCAT has a China JV with Tianjing Institute of Pharmaceutical Research, which will be responsible for developing and commercializing the drug in China, Hong Kong and Taiwan. More details...

Stock Symbol: (NSDQ: ACHN)